Record revenue, flat profit; Plant 6 catalyst ahead

Delivered ₹248.1 Cr, 18.1% YoY — precise match

Actual delivered PAT ₹17.7 Cr, flat YoY (-0.1%). Claimed ₹25 Cr is pre-ESOP adjustment (₹7.2 Cr); misleading presentation of profit growth.

Stated ₹207 Cr, 29% growth — corroborates call. However, management temperated this as not necessarily repeatable quarterly.

Mechanical completion done. Validations and customer audits ongoing. End of H1 (Q2 end, ~Sep 2026) targeting achieved per call.

TGx + Institutional ₹30 Cr this quarter, down from ~₹85–90 Cr pre-codeine discontinuation. Ex-codeine base at ₹30–35 Cr shows no growth despite management efforts.

Codeine-based products (~₹55–60 Cr annually) discontinued. TGx revenue down to ₹30 Cr run rate from ₹85–90 Cr pre-loss. Management acknowledges 'temporary hit' but recovery timeline vague.

CDMO 29% YoY growth (₹207 Cr), highest in long period. Driven by customer expansion, deeper engagement, new product launches. However, management cautioned against extrapolation; attributed to business-as-usual execution, not external tailwind.

After slower ramp, injectables 'back on track.' Infrastructure (2 lines + supportive facilities) built; future capacity addition 6–8 months if decided. No new capex announced yet.

Exports 79% YoY growth to ₹11 Cr. Small base, but management calls it 'big opportunity vertical' with high gestation. Focus on geography expansion, portfolio, plant approvals ongoing.

Management presented 37% PAT growth (ESOP-adjusted, ₹25 Cr). Actual delivered PAT ₹17.7 Cr flat YoY (-0.1%). No operating leverage despite strong topline.

CDMO grew 29%, highest in long time. Quarterly growth varies due to multiple factors; look at company level, not vertical-wise. Injectables have contributed but not specifically this quarter. No long-term factors have changed.

Growth is function of product range, geography, execution. We're working on all three. Don't give guidance. Believe sustained efforts will build long-term success.

Plant 6 similar to Plant 2 expansion. Extend existing portfolio, plant-level approvals by customers, bring in new customers. Success measured in revenue + cash flow.

Volume growth is mild even historically. Focus on execution. IPM rebound to 3.4% is welcome sign. Our growth driven by team effort and execution, not tied to IPM.

Plant 6 enables ₹1,100 Cr, expandable via debottlenecking to ₹1,250+ Cr. Peak utilization 60–65%, stretchable to 70%. Exports higher gestation; growth 'difficult to say.' Stay positive on opportunity.

TGx + institutional is lumpy. Codeine removal has impact on momentum. Acknowledge that. Long-term potential remains positive; working on geography, portfolio, alignment.

Multiple factors: increments, contractual variable manpower (linked to production), Uttarakhand minimum wage increase (retrospective). Volume-driven growth requires more manpower. No extraordinary costs.

Roughly ₹30 million/quarter, ±10–15%, initially. Depreciation reduces over time as seen prior quarters.

During period, inventory and receivables days increased due to geopolitical factors. By end, brought back to similar levels. Overall working capital maintained.

India's 2 largest cough syrup brands also discontinued codeine. Offered more cough syrups to customers, more liquid products, pack size variants. Portfolio approach, not 1:1 replacement.

Yes, now on track per customer feedback and inquiries. If capacity expansion decided, 6–8 months to add machinery, qualify, bring online. Supportive facilities already built. Discussing options.

API prices volatile. Cost-plus model insulates; customers monitor. Hard to isolate benefit or loss. Focus on supply and output, not margin shaving. Majority of growth volume-linked.

No specific changes noted. Ability to convert previous work into revenue this quarter in CDMO and Exports. No big strategic movement.

Used some Plant 6 machines in Plant 2 this quarter (contributed revenue). See ₹100–150 Cr more with Plant 6. Focus on debottlenecking existing plants and increasing Plant 6 efficiencies before new capex.

Geography expansion, portfolio, plant approvals. Lots of registration work, audits ongoing. Timing of conversion varies, but 'big opportunity vertical.'

Driven by business mix, operational efficiencies, CDMO product portfolio converted this quarter, exports growth, value-added products. Maintain material margins customer-level, not quarterly. Fortunate CDMO offset TGx loss.

Volatility continues. Inventory increase needed during quarter. Negotiations with customers fast-tracked. No stabilization yet. Very hard to say when stabilization appears.

In CDMO, if brownfield oral solids (compliant to new schedule), ~1 year. If new dosage form, different learning curve. Balance: large capacity risks attracting low-margin deals; we prefer disciplined incremental.

End of Q2 (H1 end, ~Sep 2026). 15 days plus/minus possible. Depreciation starts Q2/Q3 full impact.

Have complete visibility of markets and dossiers, but competitive-sensitive. Not sharing details on earnings call.

No. Believe incremental expansion better. Large plant risks fixed cost, desperation to fill capacity, loss of control over WC/margins/cash. Incremental discipline preferred. Ensure capacity never hurdle to growth.

Nothing final so far.

Quarterly growth not to be base. API portion lower, volume higher, but no huge single matter. Business as usual, quarter where conversion better than usual. No huge change expected.

Mechanical completion done. Validations and customer audits ongoing. Expected ~Sep 2026.

Management believes efficiency initiatives + localized capex can expand revenue ceiling. Mentioned 10–15% expansion possible beyond initial Plant 6 estimate.

OPM has held ~10–11%. NPM ~7% this quarter. No guidance for margin expansion; PAT flat YoY indicates leverage absent.

Infrastructure supportive work done. Machinery additions ₹30M depreciation initially, reducing over time.

Management deliberate on incremental capacity addition, not aggressive greenfield expansion.

TGx + Institutional fell from ₹85–90 Cr annually to ₹30–35 Cr run rate post-codeine discontinuation. Even ex-codeine base flat 3–4 quarters. Recovery mechanism (new launches, geographic expansion) unproven timeline.

API prices remain volatile due to crude-linked geopolitical factors (Middle East crisis). Inventory and receivables days stretched during quarter. Cost-plus model provides some pass-through, but lag and negotiation complexity.

CDMO 29% growth is highest in long time, but management explicitly cautioned against reading too much into a single quarter. No major new order book disclosed. Growth sourced from 'business as usual' execution, not external tailwind.

Plant 6 commercialization end of H1 FY27 (Sep 2026, ~2 months away). Mechanical completion done, but validations and customer audits ongoing. Customer adoption risk; initial utilization may lag. Depreciation drag (₹3 Cr/quarter) to offset revenue ramp.

Injectables 'back on track' after slower start than expected. New dosage form requires customer testing and learning curve. Infrastructure (2 lines + supportive facilities) in place, but conversion of inquiries to orders uncertain.